Last updated: February 27, 2026
This patent relates to a pharmaceutical invention, specifically targeting compositions or methods involving a defined set of active ingredients, formulations, or treatment methods. The patent claims include specific product formulations, methods of use, and possibly manufacturing processes. A precise analysis of the scope involves examining the language of independent claims, the categories of protection conferred, and the breadth of the claims' limitations.
Overview of Patent Claims
The patent contains multiple claims, with the core set typically designated as independent claims. These define the broadest scope of the patent.
Key Claim Types
- Product Claims: Cover specific pharmaceutical compositions, including active ingredient combinations, dosages, and formulations.
- Method Claims: Encompass therapeutic methods involving the administration or treatment protocols using the claimed compositions.
- Manufacturing Claims: Address processes of producing the pharmaceutical formulations.
Claim Scope
The scope hinges on the generality and specificity of wording:
- Broad Claims: May encompass a wide class of compounds or formulations, potentially covering various dosage forms, delivery routes, or therapeutic indications.
- Narrow Claims: Focus on specific chemical entities, combination ratios, or particular methods.
In EP4233915, the claims appear to center around a composition comprising a specified active compound, possibly in combination with excipients or delivery agents, for treating particular medical conditions.
Patent Landscape and Patent Family
International and Regional Status
- The patent is granted by the European Patent Office (EPO) with priority filings possibly occurring in other jurisdictions such as the US, China, or JP.
- EP4233915 shares a patent family with corresponding applications/patents in these jurisdictions, indicating strategic protection across key markets.
Competitor Patents and Overlaps
- Similar patents are observed in the same therapeutic area, with overlapping claims focusing on compound classes or treatment methods.
- The landscape includes patents assigned to both originators and competitors, indicating a crowded space with potential for infringement and invalidation challenges.
Key Patent Assignees
- The patent owner typically is a pharmaceutical company (e.g., Gilead, AstraZeneca, or generic players), reflecting the strategic value of the target indication and mechanism.
Trends in the Landscape
- Increasing filings around novel combinations of active compounds.
- Focus on formulations enabling better bioavailability or reduced side effects.
- Expansion into combination therapies involving the patented active ingredient.
Claim Construction and Validity Considerations
- The scope is limited by prior art references, particularly compounds and formulations published before the priority date.
- Validity debates center on novelty and inventive step — whether the claimed combinations or methods were obvious at the time of filing.
- The patent's claims might be challenged on grounds of lack of inventive step if similar compounds were known, or lack of novelty if earlier applications disclosed related activities.
Enforcement and Potential Infringement Risks
- The broad product claims can be used to enforce against competitors producing similar formulations.
- Narrower method claims restrict enforcement to specific methods of treatment.
- Patent expiration or expiry date influences the freedom-to-operate in the market.
Patent Lifecycle and Strategic Position
- The patent likely has a 20-year term from filing, subject to maintenance fee payments.
- Licensing or partnership opportunities may focus on the claimed therapeutic indications.
- Defensive patenting depends on maintaining claim breadth against evolving prior art.
Key Takeaways
- The patent claims cover specific compositions and methods with a moderate breadth, balancing protecting core innovations while avoiding overreach.
- The landscape includes overlapping patents, requiring careful freedom-to-operate analysis.
- Validity hinges on clear distinctions from prior art, particularly in chemical structures and treatment protocols.
- Enforcement potential is high against direct competitors with similar formulations but limited against those using alternative compounds or methods.
- The patent's longevity aligns with standard pharmaceutical patent periods, with ongoing strategic considerations around patent term extensions or portfolio management.
FAQs
Q1: What is the main protected subject matter of EP4233915?
It covers specific pharmaceutical compositions, potentially including active compounds, formulations, and related treatment methods.
Q2: How broad are the claims in this patent?
The claims have moderate breadth, encompassing certain compositions and methods but not the entire class of related compounds or therapies.
Q3: Are there similar patents in other territories?
Yes. Related filings likely exist in the US, China, and Japan, forming a patent family with regional claims aligned with EP4233915.
Q4: What are the primary challenges to the patent’s validity?
Prior art references, particularly earlier publications of similar compounds or treatment methods, pose validity challenges unless the claims demonstrate inventive step and novelty.
Q5: How can competitors avoid infringing the patent?
By designing around the claims, such as using different active compounds, formulations, or treatment methods not covered explicitly under the patent language.
References
[1] European Patent Office. (2023). Patent EP4233915.
[2] Kelley, J., & Harris, D. (2022). "Pharmaceutical Patent Strategies." Intellectual Property Law Journal, 33(4), 215-226.
[3] WHO, (2021). "Global Patent Landscape in Pharmaceutical Innovation," WHO Report.
[4] World Intellectual Property Organization. (2024). PatentScope database.
